Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WeDoctor and other Investors to Acquire Fertility Company Genea for $510 Million

publication date: Aug 31, 2018

WeDoctor, Mason Group and Aldworth Management agreed to pay up to $510 million to acquire an 89.5% stake in Genea, an Australian fertility treatment company. Genea's assisted reproductive technologies are used in more than 600 clinics across 60 countries. Earlier this year, the three-company consortium formed a Hong Kong IVF clinic called Reproductive Healthcare. Mason Group merged its Reproductive Healthcare subsidiary with The Women’s Clinic and brought in WeDoctor, an online China healthcare portal owned by Tencent, and Aldworth Management as strategic investors. More details....

Stock Symbol: (HK: 0700)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.